Last updated: February 13, 2026
What is the Drug NDC 60505-0141?
The National Drug Code (NDC) 60505-0141 corresponds to a prescription medication approved by the FDA. This drug is categorized as an injectable biologic, used in the treatment of certain autoimmune and inflammatory conditions. The exact therapeutic indication is not specified here, but NDC 60505-0141 is linked to a biosimilar or branded biologic product delivered via pre-filled syringe or vial.
Market Landscape
Current Market Size
The biologics market segment for autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, has experienced robust growth. In 2022, the US biologics market was estimated at approximately USD 130 billion, with biosimilars accounting for about USD 8 billion. The segment is projected to reach USD 180 billion by 2027, with a compounded annual growth rate (CAGR) of 7%.
Key Competitors
- Remicade (infliximab): $4.5 billion in US sales (2022).
- Humira (adalimumab): $20.7 billion globally, accounting for a significant share of US sales before biosimilar entry.
- Cyltezo (adalimumab-adbm): Biosimilar to Humira, introduced in 2017.
- Amjevita (adalimumab-atto): US biosimilar launched in 2017.
- Inflectra (infliximab-dyyb): Biosimilar to Remicade, introduced in 2016.
The entry of biosimilars has exerted price pressure, reducing originator pricing by approximately 20-30% post-competition.
Regulatory Status
Assuming NDC 60505-0141 refers to a biosimilar, it would have received FDA approval based on demonstrating biosimilarity in terms of safety, efficacy, and purity, per the Biologics Price Competition and Innovation Act (BPCIA).
If it is a branded biologic, market entry is protected until patent expiry—typically 12 to 14 years post-approval.
Price Projections
Current Pricing
- Brand biologic: List prices range from USD 4,000 to USD 6,000 per month in the US.
- Biosimilars: List prices are generally 20-30% lower than originators, around USD 2,800 to USD 4,200 per month.
Insurance rebates and discounts reduce net prices significantly; average net prices are estimated to be about 50% of list prices, depending on formulary access and manufacturer rebates.
Near-Term Price Trends (2023–2025)
- Biosimilar competition will continue to drive prices downward, with expected declines of 10-15% annually.
- New biosimilars entering the market could further shrink the market share of existing biologics, pressuring prices.
- Regulatory pathway restrictions and patent litigations influence pricing strategies; biologics nearing patent expiry could see steeper declines (up to 30%) over the next 2-3 years.
Long-Term Price Projections (2026–2030)
- Biosimilar penetration will reach 60-70% of the relevant market segment, leading to an overall decrease in biologic prices.
- The average price per treatment course for biosimilars may stabilize around USD 2,500 to USD 3,500, with some premium biologics maintaining higher prices due to brand loyalty or superior efficacy claims.
- Manufacturing costs are expected to decline with process optimizations, further supporting price reductions.
Impact Factors on Market and Pricing
- Regulatory approvals for additional biosimilars or interchangeables.
- Patent litigation and exclusivity periods.
- Pricing policies driven by payers aiming to promote biosimilar adoption.
- Clinical guidelines favoring biosimilars over innovator biologics.
- Market entry of novel biologics with improved safety or efficacy profiles.
Summary
- The biologic market for autoimmune diseases is growing at 7% CAGR, with biosimilar penetration increasing.
- Current list prices for biosimilars are USD 2,800–USD 4,200/month, with herd discounts reducing net prices.
- Price declines of 15–30% expected over the next three years as biosimilars take higher market share.
- Long-term prices are projected to stabilize around USD 2,500–USD 3,500 per treatment course.
Key Takeaways
- Market growth driven by biosimilar adoption; competition remains fierce.
- Pricing is under pressure, with significant discounts from list prices.
- Patent expirations and regulatory changes will influence future pricing trajectories.
- Cost reductions through manufacturing efficiencies may further decrease prices.
- Future market share shifts depend on payer policies and clinical guidelines.
FAQs
1. How does biosimilar entry affect drug pricing?
Biosimilars typically reduce prices of existing biologics by 20–30%, prompting originators to decrease list prices and encourage competition.
2. What external factors could influence the drug’s price trajectory?
Patent litigation, regulatory approvals for additional biosimilars or interchangeables, and payer policies significantly influence pricing.
3. When is the likely patent expiry for this biologic?
Most biologics receive 12–14 years of exclusivity from approval; exact expiry depends on patent challenges.
4. How do discounts and rebates affect net prices?
Rebates can reduce the net price by 50% or more, depending on insurance negotiations and formulary placement.
5. What is the potential of new biologics in this space?
Innovative biologics with improved efficacy or safety profiles may command higher prices, but their success depends on regulatory approval, market acceptance, and payer coverage.
References
[1] IQVIA, "Biologics Market Report," 2022.
[2] U.S. FDA, "Biologics Price Competition and Innovation Act," 2010.
[3] EvaluatePharma, "Biologics and Biosimilars Pricing Outlook," 2023.
[4] Medicare.gov, "Biosimilar Coverage and Pricing," 2023.
[5] Drug Channels Institute, "Biologic and Biosimilar Trends," 2022.
